Liquidia (NASDAQ:LQDA) Upgraded by Zacks Investment Research to Hold

Liquidia (NASDAQ:LQDAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company’s product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. “

A number of other research analysts have also recently issued reports on the company. BTIG Research began coverage on Liquidia in a research note on Tuesday, May 31st. They issued a “buy” rating and a $14.00 target price for the company. Bank of America assumed coverage on Liquidia in a report on Thursday, May 26th. They set a “buy” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $11.17.

LQDA stock opened at $4.42 on Thursday. The company has a market cap of $284.40 million, a P/E ratio of -5.52 and a beta of 0.35. Liquidia has a twelve month low of $2.25 and a twelve month high of $7.78. The business has a fifty day moving average of $5.40 and a 200-day moving average of $5.56.

Liquidia (NASDAQ:LQDAGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). During the same period last year, the business earned ($0.21) earnings per share. On average, analysts predict that Liquidia will post -0.98 EPS for the current year.

In other Liquidia news, insider Robert A. Lippe bought 29,628 shares of Liquidia stock in a transaction on Tuesday, May 24th. The shares were purchased at an average price of $3.38 per share, with a total value of $100,142.64. Following the acquisition, the insider now owns 90,692 shares in the company, valued at approximately $306,538.96. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Caligan Partners Lp purchased 1,764,705 shares of the company’s stock in a transaction dated Monday, April 18th. The stock was purchased at an average price of $5.10 per share, with a total value of $8,999,995.50. Following the completion of the purchase, the director now directly owns 10,093,123 shares in the company, valued at approximately $51,474,927.30. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 2,065,133 shares of company stock worth $10,395,378. 29.50% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of LQDA. Eversept Partners LP boosted its stake in Liquidia by 55.8% during the 4th quarter. Eversept Partners LP now owns 1,447,898 shares of the company’s stock valued at $7,051,000 after purchasing an additional 518,849 shares during the last quarter. Morgan Stanley lifted its position in shares of Liquidia by 337.6% during the 2nd quarter. Morgan Stanley now owns 388,312 shares of the company’s stock worth $1,111,000 after buying an additional 299,571 shares in the last quarter. Invesco Ltd. bought a new position in shares of Liquidia during the 1st quarter worth approximately $1,850,000. Soleus Capital Management L.P. bought a new position in shares of Liquidia during the 4th quarter worth approximately $1,127,000. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Liquidia by 113.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 368,849 shares of the company’s stock worth $1,796,000 after purchasing an additional 196,430 shares during the period. Institutional investors own 27.68% of the company’s stock.

Liquidia Company Profile (Get Rating)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.

See Also

Get a free copy of the Zacks research report on Liquidia (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.